BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 32967940)

  • 21. The European Medicines Agency review of entrectinib for the treatment of adult or paediatric patients with solid tumours who have a neurotrophic tyrosine receptor kinase gene fusions and adult patients with non-small-cell lung cancer harbouring ROS1 rearrangements.
    Delgado J; Pean E; Melchiorri D; Migali C; Josephson F; Enzmann H; Pignatti F
    ESMO Open; 2021 Apr; 6(2):100087. PubMed ID: 33735800
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor.
    Menichincheri M; Ardini E; Magnaghi P; Avanzi N; Banfi P; Bossi R; Buffa L; Canevari G; Ceriani L; Colombo M; Corti L; Donati D; Fasolini M; Felder E; Fiorelli C; Fiorentini F; Galvani A; Isacchi A; Borgia AL; Marchionni C; Nesi M; Orrenius C; Panzeri A; Pesenti E; Rusconi L; Saccardo MB; Vanotti E; Perrone E; Orsini P
    J Med Chem; 2016 Apr; 59(7):3392-408. PubMed ID: 27003761
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Potential Long-Term Comparative Effectiveness of Larotrectinib and Entrectinib for Second-Line Treatment of TRK Fusion-Positive Metastatic Lung Cancer.
    Roth JA; Carlson JJ; Xia F; Williamson T; Sullivan SD
    J Manag Care Spec Pharm; 2020 Aug; 26(8):981-986. PubMed ID: 32329651
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activity of Entrectinib in a Patient With the First Reported
    Sigal D; Tartar M; Xavier M; Bao F; Foley P; Luo D; Christiansen J; Hornby Z; Maneval EC; Multani P
    J Natl Compr Canc Netw; 2017 Nov; 15(11):1317-1322. PubMed ID: 29118225
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tropomyosin receptor kinase inhibitors: an updated patent review for 2016-2019.
    Bailey JJ; Jaworski C; Tung D; Wängler C; Wängler B; Schirrmacher R
    Expert Opin Ther Pat; 2020 May; 30(5):325-339. PubMed ID: 32129124
    [No Abstract]   [Full Text] [Related]  

  • 26. Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer.
    Farago AF; Le LP; Zheng Z; Muzikansky A; Drilon A; Patel M; Bauer TM; Liu SV; Ou SH; Jackman D; Costa DB; Multani PS; Li GG; Hornby Z; Chow-Maneval E; Luo D; Lim JE; Iafrate AJ; Shaw AT
    J Thorac Oncol; 2015 Dec; 10(12):1670-4. PubMed ID: 26565381
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Entrectinib: a potent new TRK, ROS1, and ALK inhibitor.
    Rolfo C; Ruiz R; Giovannetti E; Gil-Bazo I; Russo A; Passiglia F; Giallombardo M; Peeters M; Raez L
    Expert Opin Investig Drugs; 2015; 24(11):1493-500. PubMed ID: 26457764
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A newborn with a large NTRK fusion positive infantile fibrosarcoma successfully treated with larotrectinib.
    Caldwell KJ; De La Cuesta E; Morin C; Pappo A; Helmig S
    Pediatr Blood Cancer; 2020 Sep; 67(9):e28330. PubMed ID: 32452122
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
    Laetsch TW; DuBois SG; Mascarenhas L; Turpin B; Federman N; Albert CM; Nagasubramanian R; Davis JL; Rudzinski E; Feraco AM; Tuch BB; Ebata KT; Reynolds M; Smith S; Cruickshank S; Cox MC; Pappo AS; Hawkins DS
    Lancet Oncol; 2018 May; 19(5):705-714. PubMed ID: 29606586
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Foretinib Overcomes Entrectinib Resistance Associated with the
    Nishiyama A; Yamada T; Kita K; Wang R; Arai S; Fukuda K; Tanimoto A; Takeuchi S; Tange S; Tajima A; Furuya N; Kinoshita T; Yano S
    Clin Cancer Res; 2018 May; 24(10):2357-2369. PubMed ID: 29463555
    [No Abstract]   [Full Text] [Related]  

  • 31. [NTRK Gene Fusions and Treatment in NTRK Fusion-Positive Solid Cancers].
    Fukuda M; Naito Y
    Gan To Kagaku Ryoho; 2022 Oct; 49(10):1048-1050. PubMed ID: 36281593
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.
    Drilon A; Siena S; Dziadziuszko R; Barlesi F; Krebs MG; Shaw AT; de Braud F; Rolfo C; Ahn MJ; Wolf J; Seto T; Cho BC; Patel MR; Chiu CH; John T; Goto K; Karapetis CS; Arkenau HT; Kim SW; Ohe Y; Li YC; Chae YK; Chung CH; Otterson GA; Murakami H; Lin CC; Tan DSW; Prenen H; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson TR; Doebele RC;
    Lancet Oncol; 2020 Feb; 21(2):261-270. PubMed ID: 31838015
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Entrectinib: A New Selective Tyrosine Kinase Inhibitor Approved for the Treatment of Pediatric and Adult Patients with NTRK Fusionpositive, Recurrent or Advanced Solid Tumors.
    Osman HM; Tuncbilek M
    Curr Med Chem; 2022; 29(15):2602-2616. PubMed ID: 34521321
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovery and characterization of targetable NTRK point mutations in hematologic neoplasms.
    Joshi SK; Qian K; Bisson WH; Watanabe-Smith K; Huang A; Bottomly D; Traer E; Tyner JW; McWeeney SK; Davare MA; Druker BJ; Tognon CE
    Blood; 2020 Jun; 135(24):2159-2170. PubMed ID: 32315394
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Population pharmacokinetic analysis of entrectinib in pediatric and adult patients with advanced/metastatic solid tumors: support of new drug application submission.
    González-Sales M; Djebli N; Meneses-Lorente G; Buchheit V; Bonnefois G; Tremblay PO; Frey N; Mercier F
    Cancer Chemother Pharmacol; 2021 Dec; 88(6):997-1007. PubMed ID: 34536094
    [TBL] [Abstract][Full Text] [Related]  

  • 36. NTRK point mutations and their functional consequences.
    Rogers C; Morrissette JJD; Sussman RT
    Cancer Genet; 2022 Apr; 262-263():5-15. PubMed ID: 34972036
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluating entrectinib as a treatment option for non-small cell lung cancer.
    Lee J; Park S; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Expert Opin Pharmacother; 2020 Nov; 21(16):1935-1942. PubMed ID: 32736487
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer.
    Russo M; Misale S; Wei G; Siravegna G; Crisafulli G; Lazzari L; Corti G; Rospo G; Novara L; Mussolin B; Bartolini A; Cam N; Patel R; Yan S; Shoemaker R; Wild R; Di Nicolantonio F; Bianchi AS; Li G; Siena S; Bardelli A
    Cancer Discov; 2016 Jan; 6(1):36-44. PubMed ID: 26546295
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety exposure-response analyses of entrectinib in patients with advanced or metastatic solid tumors.
    Mercier F; Djebli N; González-Sales M; Jaminion F; Meneses-Lorente G
    Cancer Chemother Pharmacol; 2022 Mar; 89(3):363-372. PubMed ID: 35118559
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ETV6-NTRK2 Fusion in a Patient With Metastatic Pulmonary Atypical Carcinoid Successfully Treated With Entrectinib: A Case Report and Review of the Literature.
    Zhang W; Tian S; Li X; Chen Y; Wang X; Zhang Y; Lv L; Li Y; Shi H; Bai C
    Clin Lung Cancer; 2024 May; 25(3):215-224.e3. PubMed ID: 38584068
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.